Education:

Texas A&M University: Biomedical Science, B.S.

University of Texas School of Public Health: Disease Control, MPH

University of Texas School of Public Health: Epidemiology, PhD

About:

Stephen Gruschkus is a Senior Biostatistician at Proxima Clinical Research, Inc., a contract research organization that serves the emerging pharmaceutical and medical device industries. Stephen has over 15 years of biostatistics, clinical epidemiology, and outcomes research experience across multiple disease areas. Prior to joining the Proxima team, Stephen was a Research Biostatistician at MD Anderson Cancer Center where he was responsible for clinical trial design and provided Biostatistics support to several clinical departments. He has co-authored over 20 scientific manuscripts and has been involved in the American Society of Clinical Oncology (ASCO) and the Professional Society for Health Economics and Outcomes Research (ISPOR).

Positions and Honors:

Proxima Clinical Research, Inc., Houston, Texas
Senior Biostatistician

University of Texas MD Anderson Cancer Center, Houston, Texas
Research Biostatistician

Corrona, LLC Waltham, Massachusetts
Senior Biostatistician

Baylor College of Medicine, Houston, Texas
Senior Biostatistician

Wyle Science, Technology, and Engineering Group, Houston, Texas
Senior Statistician

Texas Children’s Hospital, Houston, Texas
Outcomes Analyst

Baylor College of Medicine, Houston, Texas
Adjunct Instructor

Xcenda, LLC, Palm Harbor, Florida
Assistant Director

US Oncology, The Woodlands, Texas
Outcomes Researcher

University of Texas MD Anderson Cancer Center, Houston, Texas
Program Coordinator

Contributions to Science:

Mr. Gruschkus is a co-author on the following manuscripts:

Ballhausen A, Urias E, Gruschkus SK, Williams M, Glover MS, Qin Y, Gombos DS, Patel SP. Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. Cancers (Basel). 2021 Jun 30;13(13):3292.  

Nieto Y, Gruschkus SK, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica. 2021 May 6.

McLemore LE, Albarracin CT, Gruschkus SK, Bassett RL Jr, Wu Y, Dhamne S, Yim I, Lin K, Bedrosian I, Sneige N, Chen H. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines. Breast Cancer Res Treat. 2021 Apr 3.  

Saberian C, Abdel-Wahab N, Abudayyeh A, Rafei H, Joseph J, Rondon G, Whited L, Gruschkus SK, Fa'ak F, Daher M, Knape C, Safa H, Shoukier M, Suarez-Almazor ME, Marcotulli M, Ludford K, Gulbis AM, Konopleva M, Ohanian M, Ravandi F, Garcia-Manero G, Oran B, Popat UR, Mehta R, Alousi AM, Daver N, Champlin R, Diab A, Al-Atrash G. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. J Immunother Cancer. 2021 Feb.

Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, Glover MS, Simien R, Diab A, Hwu P, Carter BW, Patel SP. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. J Clin Oncol. 2020 Oct 30.

Sheshadri A, Godoy M, Erasmus JJ, Gruschkus SK, Arain MH, Evans SE, Barreda-Garcia J, Chemaly RF, Dickey BF, Ost DE. Progression of the Radiologic Severity Index is associated with increased mortality and healthcare resource utilization in acute leukemia patients with pneumonia. BMJ Open Respiratory Research. 2019 Dec 23;6(1).

Nagarajan P, El-Hadad C, Gruschkus SK, Ning J, Hudgens CW, Sagiv O, Gross N, Tetzlaff MT, Esmaeli B. PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma. Invest Ophthalmol Vis Sci. 2019 May 1;60(6):2388-2398.

Reyes DP, Brinley AA, Blue RS, Gruschkus SK, Allen AT, Parazynski SE. Clinical Herpes Zoster in Antarctica as a Model for Spaceflight. Aerosp Med Hum Perform. 2017 Aug 1;88(8):784-788.

Minkowitz HS, Scranton R, Gruschkus SK, Nipper-Johnson K, Menditto L, Dandappanavar A. Development and validation of a risk score to identify patients at high risk for opioid-related adverse drug events. J Manag Care Pharm. 2014 Sep;20(9):948-58.

Minkowitz HS, Gruschkus SK, Shah M, Raju A. Adverse drug events among patients receiving postsurgical opioids in a large health system: risk factors and outcomes. Am J Health Syst Pharm. 2014 Sep 15;71(18):1556-65.

Shah M, Winfree KB, Peterson P, Gruschkus SK, Eaddy M, Green MR. Cost effectiveness of first line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous nonsmall cell lung cancer in the US outpatient setting. Lung Cancer. 2013 Oct;82(1):121-7.

Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013 Apr;33(4):383-91.

Gruschkus SK, Poston S, Eaddy M, Chaudhari S. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes. P T. 2012 Aug;37(8):46470.

Muehlenbein CE, Hoverman JR, Gruschkus SK, Forsyth M, Chen C, Lopez W, Lawson L, Hartnett HJ, Pohl G. Evaluation of the Reliability of Electronic Medical Record Data in Identifying Comorbid Conditions among Patients with Advanced Non-Small Cell Lung Cancer. Journal of Cancer Epidemiology. Volume 2011.

Nadler E, Yu E, Ravelo A, Sing A, Forsyth M, Gruschkus SK. Bevacizumab treatment to progression after chemotherapy: outcomes from a US Community practice network. Oncologist. 2011;16(4):486-96.

Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy. Value Health. 2011 Mar-Apr;14(2):253-62.

Gruschkus SK, Lairson, Dunn JK, Risser J, Du XL. Use of white blood cell growth factors and risk of therapy-related acute myeloid leukemia or myelodysplastic syndrome among elderly non-Hodgkin’s lymphoma patients. Cancer. 2010 Nov 15;116(22):5279-89.

Gruschkus SK, Lairson D, Dunn JK, Risser J, Du XL. Comparative effectiveness of white blood cell growth factors on neutropenia, infection, and survival in older people with non-Hodgkin's lymphoma treated with chemotherapy. J Am Geriatr Soc. 2010 Oct;58(10):1885-95.

Neubauer MA, Hoverman JR, Kolodziej M, Reisman L, Gruschkus SK, Hoang S, Alva AA, McArthur M, Forsyth M, Rothermel T, Beveridge RA. Cost-effectiveness of evidence-based treatment guidelines for the treatment of non-small cell lung cancer in the community setting. Journal of Oncology Practice Jan 2010.

Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Kuban DA. Influence of Obesity on Biochemical and Clinical Failure after External-Beam Radiotherapy for Localized Prostate Cancer. Cancer. 2006 Aug 1;107(3):631-9.

Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk Factors of Myelodysplastic Syndromes: A Case-Control Study. Leukemia. 2005 Nov;19(11):1912-8.

Additional Information:
OriginallY From:
Ft. Hood, Texas
Fun Fact:
I have 3 sons; I have 3 dogs; I've lived in 3 continents; my favorite number is 3.
Recent Updates
Knowledge Base Contributions
Frequently Asked Questions
Glossary Terms